Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 2
1979 1
1980 1
1981 3
1982 3
1983 11
1984 4
1985 4
1986 3
1987 4
1988 7
1989 8
1990 5
1991 8
1992 10
1993 12
1994 6
1995 5
1996 1
1997 10
1998 5
1999 10
2000 7
2001 7
2002 12
2003 7
2004 14
2005 12
2006 17
2007 8
2008 2
2009 2
2010 17
2011 13
2012 12
2013 16
2014 17
2015 34
2016 52
2017 79
2018 103
2019 141
2020 265
2021 343
2022 494
2023 537
2024 671
2025 798
2026 431

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,921 results

Results by year

Filters applied: . Clear all
Page 1
An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.
Kadowaki S, Otsuka T, Minashi K, Nishina S, Yabusaki H, Inagaki C, Nishina T, Yasui H, Matsuoka H, Machida N, Tsuda M, Nagashima F, Hosaka H, Matsubara J, Arai H, Ida S, Kimijima Y, Matsuda Y, Muto M, Muro K. Kadowaki S, et al. Gastric Cancer. 2025 Sep;28(5):955-967. doi: 10.1007/s10120-025-01641-7. Epub 2025 Jul 9. Gastric Cancer. 2025. PMID: 40632416 Free PMC article.
BACKGROUND: Nivolumab plus chemotherapy has shown efficacy in clinical trials for advanced or recurrent gastric cancer (GC). ...CONCLUSIONS: This large-scale real-world study supports the effectiveness and safety of nivolumab plus chemotherapy in untre …
BACKGROUND: Nivolumab plus chemotherapy has shown efficacy in clinical trials for advanced or recurrent gastric cancer …
Current developments in gastric cancer: from molecular profiling to treatment strategy.
Alsina M, Arrazubi V, Diez M, Tabernero J. Alsina M, et al. Nat Rev Gastroenterol Hepatol. 2023 Mar;20(3):155-170. doi: 10.1038/s41575-022-00703-w. Epub 2022 Nov 7. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36344677 Review.
Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. ...In advanced disease, only trastuzumab and some immune checkpoint inhibitors, such as nivolumab and pembrolizumab in addition to chemotherapy, have demonstrated …
Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. ...In advanced disease, only t …
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.
Boku N, Omori T, Shitara K, Sakuramoto S, Yamaguchi K, Kato K, Kadowaki S, Tsuji K, Ryu MH, Oh DY, Oh SC, Rha SY, Lee KW, Chung IJ, Sym SJ, Chen LT, Chen JS, Bai LY, Nakada T, Hagihara S, Makino R, Nishiyama E, Kang YK. Boku N, et al. Gastric Cancer. 2024 Nov;27(6):1287-1301. doi: 10.1007/s10120-024-01535-0. Epub 2024 Aug 20. Gastric Cancer. 2024. PMID: 39162872 Free PMC article. Clinical Trial.
BACKGROUND: Nivolumab + chemotherapy is now a standard of care for HER2-negative, previously untreated, unresectable or recurrent gastric/gastroesophageal junction cancer (advanced gastric cancer), but long-term follow-up data of clinical trials are limited. …
BACKGROUND: Nivolumab + chemotherapy is now a standard of care for HER2-negative, previously untreated, unresectable or recurrent gas …
Immunotherapeutic advances in gastric cancer.
Yoneda A, Kuroki T, Eguchi S. Yoneda A, et al. Surg Today. 2021 Nov;51(11):1727-1735. doi: 10.1007/s00595-021-02236-2. Epub 2021 Feb 15. Surg Today. 2021. PMID: 33590326 Review.
Three types of immunotherapy have shown promising effects against gastric cancer: immune checkpoint inhibitors, chimeric antigen rector (CAR)-T cells, and tumor vaccines. ...Based on initial evidence, we believe that immunotherapy could positively impa …
Three types of immunotherapy have shown promising effects against gastric cancer: immune checkpoint inhibitors, chimeri …
Immunotherapy for metastatic gastric cancer.
Li CF, Lian LL, Li QR, Jiao Y. Li CF, et al. World J Gastrointest Surg. 2024 Nov 27;16(11):3408-3412. doi: 10.4240/wjgs.v16.i11.3408. World J Gastrointest Surg. 2024. PMID: 39649204 Free PMC article.
Four molecular subtypes are widely used to guide and evaluate the prognosis and diagnosis and treatment of gastric cancer (GC) patients. Clinical trials of ICI treatment including Nivolumab, Pembrolizumab, Avelumab have been conducted for metastatic GC (mGC). …
Four molecular subtypes are widely used to guide and evaluate the prognosis and diagnosis and treatment of gastric cancer (GC) …
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.
Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, Wyrwicz L, Al-Haidari G, Fleitas-Kanonnikoff T, Boige V, Lordick Obermannová R, Martens UM, Gomez-Martin C, Thuss-Patience P, Arrazubi V, Avallone A, Shiu KK, Artru P, Brenner B, Buges Sanchez C, Chau I, Lorenzen S, Daum S, Sinn M, Merelli B, van Grieken NCT, Nilsson M, Collienne M, Giraut A, Smyth E. Lordick F, et al. Ann Oncol. 2025 Feb;36(2):197-207. doi: 10.1016/j.annonc.2024.10.829. Epub 2024 Nov 13. Ann Oncol. 2025. PMID: 39542422 Free article. Clinical Trial.
Patients were randomised 1 : 1 to receive standard adjuvant chemotherapy (same regimen as neoadjuvant) or nivolumab 3 mg/kg intravenously (i.v.) every 2 weeks plus ipilimumab 1 mg/kg i.v. every 6 weeks for 1 year. ...At the time of final analysis, median follow-up w …
Patients were randomised 1 : 1 to receive standard adjuvant chemotherapy (same regimen as neoadjuvant) or nivolumab 3 mg/kg intraveno …
Immunotherapy in Gastric Cancer.
Högner A, Moehler M. Högner A, et al. Curr Oncol. 2022 Mar 2;29(3):1559-1574. doi: 10.3390/curroncol29030131. Curr Oncol. 2022. PMID: 35323331 Free PMC article. Review.
Immune checkpoint inhibition is a new standard of targeted therapy in the treatment of advanced or metastatic gastric cancer (GC) and is represented in various combinations with and without chemotherapy in every therapy line within clinical trials. In advanced adeno …
Immune checkpoint inhibition is a new standard of targeted therapy in the treatment of advanced or metastatic gastric cancer ( …
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Kawazoe A, Yamaguchi K, Hamaguchi T, Narita Y, Boku S, Oshima T, Hara H, Hamamoto Y, Ishido K, Esaki T, Hosaka H, Yasui H, Koeda K, Nishina T, Tsuji Y, Fukagawa T, Goto M, Oki E, Sugimoto N, Matsuoka H, Yokoyama F, Yoshida T, Yoshida K, Oshima Y, Iwasa S. Kawazoe A, et al. Cancer Sci. 2025 Sep;116(9):2523-2536. doi: 10.1111/cas.70130. Epub 2025 Jul 6. Cancer Sci. 2025. PMID: 40618725 Free PMC article. Clinical Trial.
ONO-4578, an EP4 antagonist, alone and combined with nivolumab, showed acceptable safety profiles and signs of antitumor activity in solid tumors. The expansion part examined the safety, preliminary efficacy, and biomarkers of ONO-4578 plus nivolumab in unresectable …
ONO-4578, an EP4 antagonist, alone and combined with nivolumab, showed acceptable safety profiles and signs of antitumor activity in …
Immunotherapy for advanced gastric cancer.
Leowattana W, Leowattana P, Leowattana T. Leowattana W, et al. World J Methodol. 2023 Jun 20;13(3):79-97. doi: 10.5662/wjm.v13.i3.79. eCollection 2023 Jun 20. World J Methodol. 2023. PMID: 37456977 Free PMC article. Review.
Gastric cancer (GC) is believed to be the fifth most common cancer and the third most common cause of death worldwide. ...In this review, we sought to examine the viewpoint and development of several immunotherapy treatment modalities for advanced GC, as well …
Gastric cancer (GC) is believed to be the fifth most common cancer and the third most common cause of death worldwide. ...In t …
3,921 results